Cargando…

Targeting eosinophils: severe asthma and beyond

Recent research in the field of bronchial asthma has mainly focused on eosinophilic disease phenotype. Several trials proved the efficacy and safety profile of eosinophils and interleukin (IL)-5 targeting molecules, currently approved for severe asthma and available on the market. They include mepol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caminati, Marco, Menzella, Francesco, Guidolin, Lucia, Senna, Gianenrico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioExcel Publishing Ltd 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668506/ https://www.ncbi.nlm.nih.gov/pubmed/31391853 http://dx.doi.org/10.7573/dic.212587

Ejemplares similares

New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic
por: Caminati, Marco, et al.
Publicado: (2019)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life()
por: Bagnasco, Diego, et al.
Publicado: (2021)

The potential protective role of corticosteroid therapy in patients with asthma and COPD against COVID-19
por: Furci, Fabiana, et al.
Publicado: (2021)

Uncontrolled Asthma: Unmet Needs in the Management of Patients
por: Caminati, Marco, et al.
Publicado: (2021)

Relevance of Smoking Habit in Severe Asthma Patients: Evidence from the Severe Asthma Network in Italy (SANI) Registry
por: Caminati, Marco, et al.
Publicado: (2022)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

The clinical profile of benralizumab in the management of severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

Precision Medicine in Targeted Therapies for Severe Asthma: Is There Any Place for “Omics” Technology?
por: Galeone, Carla, et al.
Publicado: (2018)

Severe refractory asthma: current treatment options and ongoing research
por: Menzella, Francesco, et al.
Publicado: (2018)

Severe Asthma, Telemedicine, and Self-Administered Therapy: Listening First to the Patient
por: Guarnieri, Gabriella, et al.
Publicado: (2022)

TSLP and HMGB1: Inflammatory Targets and Potential Biomarkers for Precision Medicine in Asthma and COPD
por: Furci, Fabiana, et al.
Publicado: (2023)

Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry
por: Puggioni, Francesca, et al.
Publicado: (2020)

Sex Differences in Severe Asthma: Results From Severe Asthma Network in Italy-SANI
por: Senna, Gianenrico, et al.
Publicado: (2020)

Upsides and downsides of a telecounselling model of integrated asthma management between general practitioners and specialists
por: Furci, Fabiana, et al.
Publicado: (2022)

Hidden Comorbidities in Asthma: A Perspective for a Personalized Approach
por: Maule, Matteo, et al.
Publicado: (2023)

Oral health in asthmatic patients: a review: Asthma and its therapy may impact on oral health
por: Gani, Federica, et al.
Publicado: (2020)

COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control
por: Caminati, Marco, et al.
Publicado: (2021)

Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?
por: Varricchi, Gilda, et al.
Publicado: (2017)

Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights
por: Menzella, Francesco, et al.
Publicado: (2020)

Organization, Clinical and Management Indicators on the First Year of Activity of an Outpatient Clinic Dedicated to the Diagnosis and Treatment of Severe Asthma in Italy
por: Tognella, Silvia, et al.
Publicado: (2021)

Who Is Really at Risk for Anaphylaxis Due to COVID-19 Vaccine?
por: Caminati, Marco, et al.
Publicado: (2021)

Clinical response to biologicals for severe asthma: any relevance for sex in different age ranges?
por: Benoni, Roberto, et al.
Publicado: (2022)

Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity
por: Caminati, Marco, et al.
Publicado: (2021)

The intriguing possibility of using probiotics in allergen-specific immunotherapy
por: Furci, Fabiana, et al.
Publicado: (2023)

Therapeutic interventions in severe asthma
por: Canonica, Giorgio Walter, et al.
Publicado: (2016)

Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
por: Vultaggio, Alessandra, et al.
Publicado: (2023)

Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis
por: D'Amato, Maria, et al.
Publicado: (2022)

Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series
por: Menzella, Francesco, et al.
Publicado: (2021)

Severe Eosinophilic Asthma
por: Bakakos, Agamemnon, et al.
Publicado: (2019)

Tailored therapy for severe asthma
por: Menzella, Francesco, et al.
Publicado: (2015)

Asthma under/misdiagnosis in primary care setting: an observational community-based study in Italy
por: Magnoni, Maria Sandra, et al.
Publicado: (2015)

Baseline Characteristics of Patients Enrolled in Clinical Trials of Biologics for Severe Asthma as Potential Predictors of Outcomes
por: Menzella, Francesco
Publicado: (2023)

Eosinophilic bioactivities in severe asthma
por: Carr, Tara F., et al.
Publicado: (2016)

Eosinophils as Drivers of Severe Eosinophilic Asthma: Endotypes or Plasticity?
por: Van Hulst, Glenn, et al.
Publicado: (2021)

Eosinophils Target Therapy for Severe Asthma: Critical Points
por: Brussino, L., et al.
Publicado: (2018)

Towards precision medicine: The application of omics technologies in asthma management
por: Scelfo, Chiara, et al.
Publicado: (2018)

Eosinophilic inflammation: An Appealing Target for Pharmacologic Treatments in Severe Asthma
por: Vatrella, Alessandro, et al.
Publicado: (2022)

Editorial: Innate immunity and severe asthma: From microbiome to target therapy
por: Bagnasco, Diego, et al.
Publicado: (2022)

Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis
por: Caruso, Cristiano, et al.
Publicado: (2022)

SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma
por: Senna, G., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ghvar4ah0mgs69je950q38n3mb